2nd Generation glycopeptide antibiotic. Dalbavancin 500 mg.
VIAL (Pwdr. for concentrate for sol. for IV infus.): 1.×500mg. Adult pts. with ABSSSI is 1,500 mg admin. as either a single infus. of 1,500 mg or as 1,000 mg follow. one wk. later by 500 mg. See lit.
Tmt. of acute bacterial skin and skin structure infec. (ABSSSI) in adults.
C/I: Hypersens.

 

Antiplatelet Agent. Prasugrel 5, 10 mg.
F.C. TABS.:28. 1 tab ×1/d. See lit.
Prasugrel Teva, co-admin. with acetylsalicylic acid (ASA), is indic.  for the preven. of atherothrombotic events in pts. with acute coronary syndr. ( i.e. unstable angina, non-ST segment elevation MI [UA/NSTEMI] or ST segment elevation MI [STEMI] undergoing prim./ delayed percutaneous coronary intervent. (PCI).
The incr.  efficacy should be balanced with the incr. risk in pts. with bleed. tendency in those who had TIA/CVA in the past and in those above the age of 75 or wt. below 60 kg.
C/I: Hypersens.
Pts. with active bleed. (e.g.  bleed. ulcer in GI syst.).
Pts. with history of a stroke or a TIA.
Pts. with severe hep. dis.

Cholesterol Absorption Inhibitor. Ezetimibe 10mg.
TABS.: 30 ×10mg. 1 tab. ×1/d orally, taken at any time with/ without food. In comb. with statins: both medicines can be taken at the same time.
Primary hypercholesterolemia:
Ezetimibe Teva admin. with a statin  or alone are indic. as adjunct. ther. to diet for use in pts. with prim. (heterozygous familial and non-familial) hypercholesterolem.
Homozygous familial hypercholesterolem. (HoFH): Ezetimibe Teva admin. with a statin are indic. for use in pts. with HoFH. Pts. may also receive adjunct. tmt.  (e.g. LDL apheresis).
Homozygous sitosterolemia (Phytosterolemia): Ezetimibe Teva is indicated for use in pts. with homozygous familial sitosterolemia.
C/I: Hypersens.
In comb. with statins in pts. with current hep. impair.
In comb. with statins in pregnant of lactat. women.

Other sex hormones and modulators of the genital system. Prasterone 6.5 mg.
PESSARIES: 28+ 6 vag. applicat. The recomm. dose is 6.5 mg prasterone (1 pess.) admin. once dly, at bedtime. the tmt. should be reassessed at least every 6 mnths. Missed dose, should be taken as soon as the pt. remembers. However, if the next dose is due in less than 8 hrs., the pt. should skip the missed pessary. Two pessar. should not be used to make up for a forgotten dose. See lit.
Treatment of vulvar and vaginal atrophy in postmenopaus. women having moder.-severe sympt.
C/I: Hypersens.
Undiagnosed genit. bleed.
Known, past or suspect. breast canc.
Known or suspect. oestrogen-dependent malig. tumours (e.g endomet.cancer).
Untreat. endomet. hyperplasia.
Acute liver dis., or a hist. of liver dis. as long as liver funct. tests have fail. to return to normal.
Previous/ current VT (DVT, PE).
Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin defic.).
Active or recent arterial thromboemb. dis. (e.g. angina, MI).
Porphyria.

Parathyroid hormone analogue. Teriparatide 20 mcg/dose.
STARTER BOX: (CARTRIDGE 2.4 ml×1 PEN×1). 20 mcg S.C. once daily.
Tmt. of Postmenopaus. Women with Osteoporos. at High Risk for Fract.
Tmt. of postmenopaus. women with osteoporos.  at high risk for fract., defined as a history of osteoporotic fract., multiple risk fact.  for fract., or pts. who have failed or are intoler. to other availab. osteoporosis ther. In postmenopaus. women with osteoporos., Terrosa incr. bone mineral densit. (BMD), reduces the risk of vertebr. and non-vertebr. fractures.
Incr. of Bone Mass in Men with Prim. or Hypogonadal Osteoporos.at High Risk for Fract.
Indicated to incr. bone mass in men with prim. or hypogonadal osteoporos. at high risk for fract., defined as a hist. of osteoporotic fract., multiple risk fact. for fract., or pts. who have failed or are intoler. to other availab. osteoporosis ther.
Tmt. of Men and Women with Glucocorticoid-Induc. Osteoporos. at High Risk for Fract.
Tmt. of men &women with osteoporosis assoc. with sustain.system. glucocorticoid ther. (daily dosage equiv. to 5 mg or greater of prednisone) at high risk for fract., defined as a hist. of osteoporotic fracture, multiple risk fact.  for fract., or pts. who have failed or are intoler. to other available osteoporosis ther.
C/I: Hypersens. See lit.

Calcitonin gene-related peptide (CGRP) antagonists.. Fremanezumab 225 mg.
PRE-FILL. SYR. (Sol.for  S.C. inj.):1, 3×1.5ml.
PRE-FILL PEN (Sol.for  S.C. inj.): 1, 3×1.5 ml. Tmt. is intend. for pts. with at least 4 migraine days per month when initiat. tmt. with fremanezumab.
Two dosing options are avail.:
225 mg once mnthly 675 mg every 3 mnths. (quarter. dosing)
When switch. dosing regimens, the 1^st  dose of the new regimen should be admin. on the next scheduled dosing date of the prior regimen.
When initiating treatment with fremanezumab, concom. migraine prevent. tmt. may be contin. if consid. necessary by the prescriber .
The tmt. benefit should be assessed within 3 mnths. after initiat. of tmt. Any further decision to cont. tmt. should be taken on an individ. pt. basis. Evaluat. of the need to cont. tmt. is recomm. regularly thereafter.
Missed dose - dosing should resume as soon as possible on the indicat. dose and regimen. A double dose must not be admin. to make up for a missed dose.
Indicated for prophylax. of migraine in adults who have at least 4 migraine days per
month.
C/I: Hypersens. react. such as rash, pruritus, urticaria and swell. have been reported uncommon. with fremanezumab. Most react. were reported from within hrs. to one month after admin. and were mild – moder., but some led to discount. or required corticosteroid tmt. If a hypersens. reaction occurs, discount. of fremanezumab admin. should be consid.and appropriate ther. should be initiated.